A follow-up study of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs House dust mite allergy immunotherapy (Primary)
Indications Seasonal allergic rhinitis
Focus Therapeutic Use

Most Recent Events

24 Oct 2017 Results from a subset of initially randomized 36 patients (n = 19) presented in an ASIT Biotech media release.
24 Oct 2017 According to an ASIT Biotech media release, this trial was performed at the Carl Gustav Carus University Hospital in Dresden, Germany.
24 Oct 2017 Status changed from planning to active, no longer recruiting, according to an ASIT Biotech media release.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight